Record overview
Status and phase
Status: COMPLETED
Phase: PHASE2
Sponsor: Bristol-Myers Squibb
Condition: Pan Tumor
NCT03668119
A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: stale_update_signal
Results signal: Low Signal
Operational burden: large_enrollment_target_signal | rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.